What's new in NeuroNEXT?
NeuroNEXT • Network for Excellence in Neuroscience Clinical Trials
The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry. The network is designed to expand the National Institute of Neurological Disorders and Stroke's (NINDS) capability to test promising new therapies, increase the efficiency of clinical trials before embarking on larger studies, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders.
The NeuroNEXT program aims to:
• Provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. The network includes multiple Clinical Sites, one Clinical Coordinating Center (CCC) and one Data Coordinating Center (DCC).
•Support scientifically sound, possibly biomarker-informed, Phase II clinical trials that provide data for clear go/no-go decisions.
• Energize and mobilize federal, industry, foundations and patient advocacy partners by leveraging existing relationships between NINDS and NeuroNEXT to organize high impact Phase II clinical trials for neurological disorders.
• Expand the pool of experienced clinical investigators and research staff who are prepared to be leaders of multicenter clinical research trials.
• Working with NeuroNEXT is a cooperative venture between NINDS, the NeuroNEXT network and the applicant.